SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology…
Study reveals that 5'-tRNAGly(GCC) is a key regulator of gene expression and a potential therapeutic target in cancer SEOUL, Dec.…
Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing…
FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…
Business Activity Index at 53.7%; New Orders Index at 53.7%; Employment Index at 51.5%; Supplier Deliveries Index at 49.5% TEMPE, Ariz., Dec.…
Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo…
FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering…
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular…
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA…
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…